Opus Genetics (IRD) Cash from Operations Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.97% |
| Dec 31, 2025 | -17.67% |
| Sep 30, 2025 | -42.28% |
| Jun 30, 2025 | -73.62% |
| Mar 31, 2025 | -65.15% |
| Dec 31, 2024 | -28.44% |
| Sep 30, 2024 | -16.62% |
| Jun 30, 2024 | -32.19% |
| Mar 31, 2024 | -5.47% |
| Dec 31, 2023 | 24.44% |
| Sep 30, 2023 | 6.34% |
| Jun 30, 2023 | 17.31% |
| Mar 31, 2023 | 8.22% |
| Dec 31, 2022 | 57.76% |
| Sep 30, 2022 | -5.47% |
| Jun 30, 2022 | 1.46% |
| Mar 31, 2022 | -8.16% |
| Dec 31, 2021 | -30.47% |
| Sep 30, 2021 | -2.80% |
| Jun 30, 2021 | 3.09% |
| Mar 31, 2021 | -10.36% |
| Dec 31, 2020 | 0.23% |
| Sep 30, 2020 | 25.18% |
| Jun 30, 2020 | 31.77% |
| Mar 31, 2020 | 28.94% |
| Dec 31, 2019 | 29.96% |
| Sep 30, 2019 | 1.78% |
| Jun 30, 2019 | 9.35% |
| Mar 31, 2019 | -11.20% |
| Dec 31, 2018 | -15.49% |
| Sep 30, 2018 | -19.91% |
| Jun 30, 2018 | -12.21% |
| Mar 31, 2018 | -29.26% |
| Dec 31, 2017 | -28.11% |
| Sep 30, 2017 | -15.88% |
| Jun 30, 2017 | -15.67% |
| Mar 31, 2017 | -16.82% |
| Dec 31, 2016 | 21.08% |
| Sep 30, 2016 | 0.25% |
| Jun 30, 2016 | 0.01% |
| Mar 31, 2016 | -7.91% |
| Dec 31, 2015 | -12.74% |
| Sep 30, 2015 | -23.16% |